Mogrify: Using Big Data To Transform Development Of Cell Therapies

Money in the bank, biotech legacies onboard, a fresh partnership, an emerging internal cell therapy pipeline and a grand vision for the broad-scale application of its technology – has Mogrify got it all? The biotech’s chief business officer, Karin Schmitt, talks to In Vivo about the group’s near- and long-term goals.

UK-based Mogrify, Ltd., which emerged from stealth mode in 2019, is using a big data-based platform technology to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies. The company boasts Jane Osbourn, former vice president of R&D at MedImmune, as its chair, and Darrin Disley, former CEO of gene-editing firm Horizon Discovery Group PLC, as its CEO.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Building The Worm Atlas For I&I Breakthroughs

10 Apr 2025

• By Ian Taylor

The next big thing in auto-immune therapies: worms. Or so a young California biotech believes. Holoclara is pioneering a new class of medicines derived from intestinal worms to revolutionize the treatment of autoimmune diseases, allergies, and more.

Podcast: OSE Immunotherapeutics’ CEO On Ulcerative Colitis Asset

09 Apr 2025

• By David Wild

Nicolas Poirier, CEO of French biotech OSE Immunotherapeutics, spoke with In Vivo about the company's anti-IL-7R antibody, lusvertikimab, on the heels of impressive ulcerative colitis data presented at the 2025 European Crohn's and Colitis Organization meeting.

Rising Leaders 2025: Amir Hefni Puts Optimism Into Action At Resolution Therapeutics

07 Apr 2025

• By Jo Shorthouse

In Vivo Rising Leader Amir Hefni, CEO of Resolution Therapeutics, discusses the company's advancements in macrophage cell therapies for inflammatory and fibrotic diseases, and his transition from big pharma to biotech leadership.

How Charl Van Zyl Is Reimagining Lundbeck

02 Apr 2025

• By David Wild

Lundbeck CEO Charl van Zyl spoke with In Vivo about the Danish company’s multipronged transformation, one that involves a rethink of company culture, pipeline strategy and a sharpened focus on innovation in rare neurological disorders.

In Vivo’s 2025 Rising Leaders

07 Apr 2025

• By Jo Shorthouse

The sixth annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.